Publicaciones en las que colabora con Fernando Sarramea Crespo (18)

2009

  1. Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 173, Núm. 2, pp. 88-93

2008

  1. Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Núm. 1, pp. 257-266

2007

  1. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia

    European Neuropsychopharmacology, Vol. 17, Núm. 6-7, pp. 456-463

  2. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder

    European Psychiatry, Vol. 22, Núm. 8, pp. 505-512

  3. Marked hypofrontality in clozapine-responsive patients

    Pharmacopsychiatry, Vol. 40, Núm. 4, pp. 157-162

  4. No association between dorsolateral prefrontal gray matter deficit and N-acetyl aspartate ratios in schizophrenia

    Neuropsychobiology, Vol. 54, Núm. 3, pp. 171-178

2006

  1. Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 256, Núm. 2, pp. 106-111

2005

  1. Association between excessive frontal cerebrospinal fluid and illness duration in males but not in females with schizophrenia

    European Psychiatry, Vol. 20, Núm. 4, pp. 332-338

  2. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia

    Schizophrenia Research, Vol. 80, Núm. 1, pp. 61-71

  3. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration

    Schizophrenia Research, Vol. 73, Núm. 2-3, pp. 209-219

  4. Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity

    Journal of Psychiatric Research, Vol. 39, Núm. 2, pp. 117-127

2004

  1. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients

    Psychiatry Research - Neuroimaging, Vol. 131, Núm. 1, pp. 45-56

2003

  1. Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 124, Núm. 3, pp. 153-161

  2. Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 124, Núm. 3, pp. 163-175

  3. Cerebral metabolic patterns in chronic and recent-onset schizophrenia

    Psychiatry Research - Neuroimaging, Vol. 122, Núm. 2, pp. 125-135

2002

  1. Association between relative temporal and prefrontal sulcal cerebrospinal fluid and illness duration in schizophrenia

    Schizophrenia Research, Vol. 58, Núm. 2-3, pp. 305-312

  2. Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia

    Neurotoxicity Research, Vol. 4, Núm. 5-6, pp. 437-451

2001

  1. P300 amplitude as a possible correlate of frontal degeneration in schizophrenia

    Schizophrenia Research, Vol. 49, Núm. 1-2, pp. 121-128